Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EDAP TMS SAFOCL · Entity 6325 | Director | August 14, 2026 | August 17, 2026 |
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Director | June 25, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EDAP TMS SA
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,100 |
Reported balance
After 2026-08-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 10,000 · Balance 15,100 F1: Common Stock for the issuer refers to the issuer's ordinary shares. F2: The reported securities represent ordinary shares purchased by the reporting person in connection with an underwritten public offering of American Depositary Shares, each of which represents one ordinary share of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock for the issuer refers to the issuer's ordinary shares.
F2: The reported securities represent ordinary shares purchased by the reporting person in connection with an underwritten public offering of American Depositary Shares, each of which represents one ordinary share of the issuer.
Senti Biosciences Holdings, Inc.
Report date June 25, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2035-06-24 | Direct | 21,950 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 21,950 · Balance 21,950 F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 10:04 UTC | EDAP TMS SA FOCL · Entity 6325 | PurchaseCommon Stock | 10,000 | $4.75 | $47,500.00 |
DisclosureSEC source: 0001829126-26-008926 · ownership.xml · nonDerivative · entry 1 Schulz Fran · CIK 0002046804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,100 F1 · security: Common Stock for the issuer refers to the issuer's ordinary shares. F2 · security: The reported securities represent ordinary shares purchased by the reporting person in connection with an underwritten public offering of American Depositary Shares, each of which represents one ordinary share of the issuer. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 23:53 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 21,950 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000950170-25-091155 · ownership.xml · derivative · entry 1 Schulz Fran · CIK 0002046804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,950 Underlying: Common Stock · 21,950 shares Expires 2035-06-24 F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:21 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 43,900 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001854270-25-000032 · wk-form4_1741724456.xml · derivative · entry 1 Schulz Fran · CIK 0002046804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,900 Underlying: Common Stock · 43,900 shares Expires 2035-03-06 F1 · derivative.exercise_date: 100% of the shares underlying this option vest on the first anniversary of the date of grant, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:17 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001854270-24-000123 · wk-form4_1733865447.xml · derivative · entry 1 Schulz Fran · CIK 0002046804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-12-08 F1 · derivative.exercise_date: The shares underlying this option vest in 36 substantially equal monthly installments over three years from December 9, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.